Nuvation Bio NUVB Research And Development Service Revenue — Deferred Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's research and development service revenue — deferred revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's research and development service revenue — deferred revenue?
- Nuvation Bio (NUVB) reported research and development service revenue — deferred revenue of $18.4M in Q1 2026.
- How has Nuvation Bio's research and development service revenue — deferred revenue changed year-over-year?
- Nuvation Bio's research and development service revenue — deferred revenue increased by 9100.0% year-over-year, from $200K to $18.4M.
- What does research and development service revenue — deferred revenue mean?
- This represents the obligation to provide research and development services to a customer for which the company has already received consideration or has an unconditional right to consideration. It serves as a measure of deferred revenue that will be recognized as performance obligations are satisfied over time. A high balance indicates significant future service commitments and potential revenue visibility.